vs
Side-by-side financial comparison of Avidbank Holdings, Inc. (AVBH) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
ARS Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($28.1M vs $28.0M, roughly 1.0× Avidbank Holdings, Inc.). Avidbank Holdings, Inc. runs the higher net margin — 32.3% vs -147.1%, a 179.4% gap on every dollar of revenue.
Avidbank Holdings, Inc. is a U.S.-based financial holding company operating through its subsidiary AvidBank. It offers commercial banking products and services primarily to small and medium-sized enterprises, business owners, and high-net-worth individuals across California, including commercial loans, deposit accounts, cash management, and customized financing solutions for sectors like manufacturing, technology, real estate and professional services.
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
AVBH vs SPRY — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $28.0M | $28.1M |
| Net Profit | $9.0M | $-41.3M |
| Gross Margin | — | — |
| Operating Margin | — | -147.6% |
| Net Margin | 32.3% | -147.1% |
| Revenue YoY | — | -67.6% |
| Net Profit YoY | 65.9% | -182.8% |
| EPS (diluted) | $0.84 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $28.0M | — | ||
| Q4 25 | $26.8M | $28.1M | ||
| Q3 25 | $48.0K | $32.5M | ||
| Q2 25 | $21.8M | $15.7M | ||
| Q1 25 | — | $8.0M | ||
| Q4 24 | — | $86.6M | ||
| Q3 24 | — | $2.1M | ||
| Q2 24 | — | $500.0K |
| Q1 26 | $9.0M | — | ||
| Q4 25 | $6.9M | $-41.3M | ||
| Q3 25 | $-37.7M | $-51.2M | ||
| Q2 25 | $5.8M | $-44.9M | ||
| Q1 25 | — | $-33.9M | ||
| Q4 24 | — | $49.9M | ||
| Q3 24 | — | $-19.1M | ||
| Q2 24 | — | $-12.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | -147.6% | ||
| Q3 25 | -110491.7% | -163.7% | ||
| Q2 25 | 38.0% | -302.9% | ||
| Q1 25 | — | -466.3% | ||
| Q4 24 | — | 54.5% | ||
| Q3 24 | — | -1051.6% | ||
| Q2 24 | — | -3068.0% |
| Q1 26 | 32.3% | — | ||
| Q4 25 | 25.9% | -147.1% | ||
| Q3 25 | -78614.6% | -157.4% | ||
| Q2 25 | 26.6% | -285.6% | ||
| Q1 25 | — | -425.7% | ||
| Q4 24 | — | 57.7% | ||
| Q3 24 | — | -925.0% | ||
| Q2 24 | — | -2503.2% |
| Q1 26 | $0.84 | — | ||
| Q4 25 | $0.65 | $-0.41 | ||
| Q3 25 | $-4.12 | $-0.52 | ||
| Q2 25 | $0.75 | $-0.46 | ||
| Q1 25 | — | $-0.35 | ||
| Q4 24 | — | $0.52 | ||
| Q3 24 | — | $-0.20 | ||
| Q2 24 | — | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $245.0M |
| Total DebtLower is stronger | $55.0M | $96.4M |
| Stockholders' EquityBook value | $287.2M | $114.3M |
| Total Assets | $2.5B | $327.7M |
| Debt / EquityLower = less leverage | 0.19× | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $245.0M | ||
| Q3 25 | — | $288.2M | ||
| Q2 25 | — | $240.1M | ||
| Q1 25 | — | $275.7M | ||
| Q4 24 | — | $314.0M | ||
| Q3 24 | — | $204.6M | ||
| Q2 24 | — | $218.7M |
| Q1 26 | $55.0M | — | ||
| Q4 25 | $60.0M | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $287.2M | — | ||
| Q4 25 | $278.4M | $114.3M | ||
| Q3 25 | $273.1M | $147.7M | ||
| Q2 25 | $204.4M | $192.3M | ||
| Q1 25 | — | $229.0M | ||
| Q4 24 | — | $256.8M | ||
| Q3 24 | — | $201.0M | ||
| Q2 24 | — | $215.2M |
| Q1 26 | $2.5B | — | ||
| Q4 25 | $2.5B | $327.7M | ||
| Q3 25 | $2.4B | $372.8M | ||
| Q2 25 | $2.4B | $313.5M | ||
| Q1 25 | — | $327.3M | ||
| Q4 24 | — | $351.2M | ||
| Q3 24 | — | $217.6M | ||
| Q2 24 | — | $222.0M |
| Q1 26 | 0.19× | — | ||
| Q4 25 | 0.22× | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-43.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $-43.5M | ||
| Q3 25 | $12.4M | $-47.0M | ||
| Q2 25 | $10.7M | $-39.6M | ||
| Q1 25 | — | $-40.7M | ||
| Q4 24 | — | $42.0M | ||
| Q3 24 | — | $-14.5M | ||
| Q2 24 | — | $-7.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $12.4M | $-47.2M | ||
| Q2 25 | $10.6M | $-39.6M | ||
| Q1 25 | — | $-40.8M | ||
| Q4 24 | — | $41.7M | ||
| Q3 24 | — | $-14.6M | ||
| Q2 24 | — | $-7.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 25783.3% | -145.4% | ||
| Q2 25 | 48.6% | -252.2% | ||
| Q1 25 | — | -512.1% | ||
| Q4 24 | — | 48.2% | ||
| Q3 24 | — | -706.3% | ||
| Q2 24 | — | -1463.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.0% | ||
| Q3 25 | 72.9% | 0.6% | ||
| Q2 25 | 0.3% | 0.3% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 6.8% | ||
| Q2 24 | — | 7.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.84× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.84× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVBH
| Net Interest Income | $26.5M | 95% |
| Noninterest Income | $1.5M | 5% |
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
